STOCK TITAN

Adial Pharmaceuticals, Inc - ADIL STOCK NEWS

Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company dedicated to developing treatments for addiction and related disorders. The company's primary focus is on creating personalized therapies that address the unique needs of individuals suffering from substance abuse. Adial's flagship product, AD04, is a serotonin-3 receptor antagonist aimed at treating Alcohol Use Disorder (AUD) in patients with specific genetic profiles. AD04 has shown promise in reducing excessive drinking in heavy drinking patients and has been investigated in the company's ONWARD™ pivotal Phase 3 clinical trial. The active ingredient in AD04 is ondansetron, which is commonly used to prevent nausea and vomiting, and now brings potential benefits in addiction treatment.

Adial leverages its expertise in pharmacogenomics to develop therapies that are tailored to the genetic makeup of patients. This approach has the potential to revolutionize the treatment of addiction by providing more effective and safer treatment options. The company recently regained compliance with Nasdaq's listing requirements by maintaining a stockholders' equity of at least $2.5 million. Adial has also been active in forming strategic partnerships, including an agreement with Adovate, LLC, which could yield up to $83 million in milestone payments and commercial royalties.

Adial's intellectual property portfolio is robust, with multiple patents protecting the combination of its genetic diagnostics and AD04 for the treatment of AUD, Opioid Use Disorder (OUD), and other dependencies. The company's recent awards include the 2023 Best Practices Technology Innovation Leadership Award from Frost & Sullivan. Financially, Adial is in a stable position, with cash and cash equivalents allowing it to fund operations into the first quarter of 2025. The company's research and development expenses have been judiciously managed, ensuring that resources are effectively utilized.

Recent studies have underscored the safety and efficacy of AD04, highlighting its favorable liver safety profile compared to placebo and its potential to treat other addictive disorders like gambling and obesity. Adial has initiated new activities related to its clinical development plan, including two parallel Phase 3 clinical trials of AD04 to support its approval in the shortest timeframe possible. The company is also engaging with the FDA to refine its study designs and enhance the likelihood of regulatory success.

Adial Pharmaceuticals continues to make significant strides in its mission to develop innovative solutions for addiction treatment, offering hope to millions affected by these disorders worldwide.

Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced that CEO William Stilley will present at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 AM ET, accessible for 90 days. Adial is developing AD04, a treatment for Alcohol Use Disorder, currently undergoing a pivotal Phase 3 clinical trial. The company aims to treat various addictions and is working on adenosine analogs for pain management and other disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
conferences
-
Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced it received $720,000 from an $800,000 private placement, originally disclosed on November 10, 2021. The shares, priced at $4.00 each, were fully subscribed with 200,000 shares purchased. This funding was confirmed following the SEC's Notice of Effectiveness for the Form S-3 Registration Statement. Adial is focused on addiction therapies, particularly its lead investigational drug, AD04, which is under evaluation in the ONWARD™ Phase 3 trial aimed at treating Alcohol Use Disorder.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.56%
Tags
none
-
Rhea-AI Summary

Adial Pharmaceuticals has appointed Cary J. Claiborne as Chief Operating Officer, while he remains on the Board of Directors. Claiborne's role includes overseeing strategic growth initiatives and commercial preparations for AD04, aimed at treating Alcohol Use Disorder (AUD). CEO William Stilley emphasized Claiborne's extensive experience in the biopharmaceutical sector, particularly in addiction treatment. Claiborne expressed enthusiasm for advancing the company’s therapeutic pipeline, including the promising AD04 and Purnovate's adenosine platform, which holds significant market potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.14%
Tags
management
Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) reported promising preclinical results for its lead compound PNV2 in treating triple negative breast cancer. The study showcased that PNV2 significantly reduced metastatic tumors in the lungs of mice compared to a control group, with luciferase activity indicating much lower cancer presence. Purnovate, Adial's subsidiary, plans to advance PNV2 to clinical trials in 2022, overcoming past solubility challenges associated with adenosine analogs. The company remains focused on its ongoing Phase 3 trial for its lead drug candidate for Alcohol Use Disorder.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.18%
Tags
-
Rhea-AI Summary

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) will host a conference call on November 18, 2021, at 11:00 A.M. ET to discuss clinical updates and business developments. Investors can join via phone or listen online. The conference will feature information on the lead investigational drug, AD04, currently in a pivotal Phase 3 trial for Alcohol Use Disorder (AUD). AD04 showed promising Phase 2b results with significant reductions in drinking behaviors. A replay of the call will be accessible for a year, reflecting ongoing investor engagement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
conferences
-
Rhea-AI Summary

Adial Pharmaceuticals has secured $1,255,000 in funding to bolster its clinical trial initiatives for the non-opioid pain treatment candidate PNV-5030. This includes $800,000 from a private placement at $4.00 per share and $455,000 from the exercise of stock options by Mark Howard Peikin, the Chief Strategy Officer. Peikin's cash exercise supports drug development, enhancing Adial's financial position for ongoing and future trials, specifically the pivotal Phase 3 trial of its lead drug for Alcohol Use Disorder (AUD).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
Rhea-AI Summary

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) announced a conference call on November 18, 2021, at 11:00 A.M. ET to provide updates on its clinical trials and business progress. The company is developing AD04, a serotonin-3 receptor antagonist for treating Alcohol Use Disorder (AUD). AD04 is in a pivotal Phase 3 trial and has shown promising Phase 2b results, indicating a significant reduction in drinking frequency and quantity with no major safety concerns. Adial also explores treatments for other addictive disorders and develops adenosine analogs for pain management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.44%
Tags
none
-
Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced the appointment of Cary J. Claiborne to its Board of Directors, expanding the board to seven members. Claiborne brings extensive experience, having previously served as CFO of Indivior PLC and Sucampo Pharmaceuticals. His expertise in governance and finance is expected to support Adial as it advances its Phase 3 clinical trial of AD04 for alcohol use disorder and prepares for potential commercialization. Adial aims to leverage Claiborne's track record to enhance its corporate governance and strategic initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
management
-
Rhea-AI Summary

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) announced promising pre-clinical results for PNV-5030, a potential pain treatment. The compound showed over 1000-fold selectivity over the adenosine A1 receptor and significantly reduced pain in a mouse model. When combined with morphine, PNV-5030 achieved similar pain reduction to higher morphine doses. Purnovate, a subsidiary of Adial, plans to advance PNV-5030 into clinical trials in 2022, aiming to provide an alternative or complement to opioid use.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
Rhea-AI Summary

Adial Pharmaceuticals announced positive pre-clinical results for PNV-5030, indicating its potential to reduce opioid use and alleviate pain. PNV-5030 exhibited over 1000-fold selectivity over the adenosine A1 receptor and demonstrated superior solubility compared to other compounds in its class. In mouse models, PNV-5030 alone provided significant pain relief similar to low doses of morphine, and remarkably, when combined with morphine, it achieved pain relief equivalent to a higher morphine dose. The company plans to advance PNV-5030 into clinical trials in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags

FAQ

What is the current stock price of Adial Pharmaceuticals (ADIL)?

The current stock price of Adial Pharmaceuticals (ADIL) is $1.015 as of November 5, 2024.

What is the market cap of Adial Pharmaceuticals (ADIL)?

The market cap of Adial Pharmaceuticals (ADIL) is approximately 6.4M.

What is Adial Pharmaceuticals' main focus?

Adial Pharmaceuticals focuses on developing personalized treatments for addiction and related disorders, leveraging pharmacogenomics to tailor therapies to individual genetic profiles.

What is AD04?

AD04 is Adial's lead investigational new drug, a serotonin-3 receptor antagonist used to treat Alcohol Use Disorder (AUD) in heavy drinking patients with specific genetic profiles.

What recent achievements has Adial Pharmaceuticals made?

Adial has regained compliance with Nasdaq's listing requirements, formed a strategic partnership with Adovate, LLC, and received multiple patents protecting its genetic diagnostics and AD04.

How is AD04 different from other treatments for AUD?

AD04 is genetically targeted, meaning it is tailored to patients with specific genetic profiles, enhancing its effectiveness and safety compared to conventional treatments.

What financial position is Adial Pharmaceuticals currently in?

Adial is financially stable, with cash and cash equivalents allowing it to fund operations into the first quarter of 2025. The company is also managing its research and development expenses efficiently.

What are the potential applications of AD04 beyond AUD?

AD04 has shown potential to treat other addictive disorders such as Opioid Use Disorder (OUD), gambling, and obesity.

How has Adial Pharmaceuticals engaged with regulatory agencies?

Adial has received favorable feedback from both US and European regulators, helping to refine its clinical development plan and enhance the likelihood of regulatory success for AD04.

What recent studies have been conducted on AD04?

Recent studies have highlighted AD04's safety profile, particularly its minimal impact on liver function, and its efficacy in reducing heavy drinking in patients with specific genetic markers.

What strategic partnerships has Adial Pharmaceuticals formed?

Adial has partnered with Adovate, LLC, securing potential milestone payments and royalties, and is in discussions with other potential strategic partners to support the development and launch of AD04.

What are the next steps for Adial's clinical development plan?

Adial plans to conduct two parallel Phase 3 clinical trials of AD04 and engage with the FDA to refine study designs, aiming for regulatory approval and commercialization.

Adial Pharmaceuticals, Inc

Nasdaq:ADIL

ADIL Rankings

ADIL Stock Data

6.41M
6.41M
1.8%
4.43%
0.8%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHARLOTTESVILLE